+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A novel TLR4-binding peptide that inhibits LPS-induced activation of NF-kappaB and in vivo toxicity



A novel TLR4-binding peptide that inhibits LPS-induced activation of NF-kappaB and in vivo toxicity



European Journal of Pharmacology 594(1-3): 152-156



Lipopolysaccharide (LPS) is a component of the outer membrane of Gram-negative bacteria. It is a ligand for Toll-like receptor 4 (TLR4), which plays an essential role in innate immunity. Macrophages and dendritic cells exposed to LPS overproduce proinflammatory mediators, leading to septic shock. In this study, we screened for peptides that associate with TLR4 with a yeast two-hybrid screen using the human TLR4 extracellular domain as bait. A peptide (STM28) isolated from the screen inhibited LPS-induced nuclear factor-kappaB (NF-kappaB) activation in human and mouse macrophage cells and interacted with TLR4 in yeast and mammalian cells. STM28 showed no inhibitory effects against NF-kappaB activation induced by TLR1/2, TLR3 and TLR9 ligands in a mouse macrophage cell line, RAW 264. In addition, STM28 suppressed LPS-induced tumor necrosis factor-alpha production by differentiated THP-1 cells. Moreover, LPS-induced lethality in d-galactosamine-sensitized mice was significantly repressed by STM28 in a dose-dependent manner. These results demonstrate that STM28 selectivity inhibits TLR4-induced macrophage activation, and suggest that STM28 may have utility as a novel therapeutic agent for Gram-negative bacterial sepsis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051190397

Download citation: RISBibTeXText

PMID: 18700140

DOI: 10.1016/j.ejphar.2008.07.037


Related references

Fasciola hepatica fatty acid binding protein inhibits TLR4 activation and suppresses the inflammatory cytokines induced by lipopolysaccharide in vitro and in vivo. Journal of Immunology 194(8): 3924-3936, 2015

Alpha-lipoic acic inhibits lipopolysaccharide-induced NF-kappaB activation and adhesion molecule expression in vivo. Free Radical Biology & Medicine 35(Suppl. 1): S77, 2003

Prevention of NF-kappaB activation in vivo by a cell-permeable NF-kappaB inhibitor peptide. American Journal of Physiology. Lung Cellular and Molecular Physiology 289(4): L536-L544, 2005

Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Research 70(6): 2379-2388, 2010

Alpha-lipoic acid inhibits lipopolysaccharide-induced NF-kappaB activation and adhesion molecule expression in mice in vivo. Circulation 108(17 Suppl.): IV-283, 2003

Purification of a peptide from seahorse, that inhibits TPA-induced MMP, iNOS and COX-2 expression through MAPK and NF-kappaB activation, and induces human osteoblastic and chondrocytic differentiation. Chemico-Biological Interactions 184(3): 413-422, 2010

Heat shock inhibits radiation-induced activation of NF-kappaB via inhibition of I-kappaB kinase. Journal of Biological Chemistry 274(33): 23061-7, 1999

Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption. Bone 46(5): 1369-1379, 2010

Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Molecular Immunology 45(10): 2929-2936, 2008

WDR34 is a novel TAK1-associated suppressor of the IL-1R/TLR3/TLR4-induced NF-kappaB activation pathway. Cellular and Molecular Life Sciences 66(15): 2573-2584, 2009

Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. Journal of Immunology 169(11): 6490-6497, 2002

Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase. Gastroenterology 128(7): 2042-2053, 2005

Thioredoxin inhibits tumor necrosis factor- or interleukin-1-induced NF-kappaB activation at a level upstream of NF-kappaB-inducing kinase. Antioxidants and Redox Signaling 2(1): 83-92, 2000